Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS).
INVESTORS OF SYROS PHARMACEUTICALS STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL INFO@KEHOELAWFIRM.COM TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SYROS SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
After the market closed on November 12, 2024, Syros announced that "[o]n November 12, 2024, an event of default occurred under the Loan and Security Agreement dated February 12, 2020 . . . between Syros Pharmaceuticals, Inc. . . . and Oxford Finance LLC (the "Lender"), as a result of the failure of the Company's SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression to meet its primary endpoint of complete response rate."
On this news, the stock price of Syros was down more than 86% during intraday trading on November 13, 2024.
Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.
This press release may constitute attorney advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229794
